心源性休克幸存者的精神心理后遗症与管理:一项全国性人群研究
该研究基于韩国国民健康保险服务数据库,纳入2012年1月至2022年12月因心源性休克入住ICU并存活出院的成人患者,排除已有精神科诊断者,最终纳入112,297例。中位随访3.5年(四分位距1.26–6.56)期间,11,166例(9.9%)新发精神障碍(包括抑郁障碍、失眠、焦虑障碍和精神分裂症谱系障碍),这些障碍与主要终点风险显著升高相关(校正HR 1.08,95%CI 1.04–1.13),但焦虑障碍除外。在精神障碍患者中,启动精神药物治疗与主要终点降低44%(校正HR 0.56,95%CI 0.53–0.59)及全因死亡降低49%(校正HR 0.51,95%CI 0.48–0.55)相关。作者认为,及时的精神药物干预可能显著改善长期临床结局,应整合到ICU后照护路径中。
要点
- 心源性休克存活出院患者中,中位随访3.5年(IQR 1.26–6.56)期间9.9%(11,166/112,297)新发精神障碍,包括抑郁障碍、失眠、焦虑障碍和精神分裂症谱系障碍。
- 新发精神障碍与主要终点(全因死亡、心肌梗死、卒中、冠状动脉血运重建或心力衰竭住院的复合终点)风险显著升高相关(校正HR 1.08,95%CI 1.04–1.13),但焦虑障碍除外。
- 在精神障碍患者中,启动精神药物治疗(抗抑郁药、抗精神病药、抗焦虑药或镇静催眠药)与主要终点降低44%(校正HR 0.56,95%CI 0.53–0.59)及全因死亡降低49%(校正HR 0.51,95%CI 0.48–0.55)相关。
- 作者认为,应及时对心源性休克幸存者的精神障碍进行药物干预,并将其整合到ICU后照护路径中。
适用人群与场景
- 2012年1月至2022年12月因心源性休克入住ICU并存活出院的成人患者,排除已有精神科诊断者,最终纳入112,297例。
处置流程与药物剂量
- 在精神障碍患者中,启动精神药物治疗包括抗抑郁药、抗精神病药、抗焦虑药或镇静催眠药,与主要终点降低44%(校正HR 0.56,95%CI 0.53–0.59)及全因死亡降低49%(校正HR 0.51,95%CI 0.48–0.55)相关;药物使用作为时间依赖协变量建模。
研究设计与关键结果
- 研究类型:全国性人群-based队列研究,使用韩国国民健康保险服务数据库,纳入112,297例心源性休克存活出院成人患者。
- 中位随访3.5年(IQR 1.26–6.56)期间,11,166例(9.9%)新发精神障碍,包括抑郁障碍、失眠、焦虑障碍和精神分裂症谱系障碍。
- 新发精神障碍与主要终点风险显著升高相关(校正HR 1.08,95%CI 1.04–1.13),但焦虑障碍除外;主要终点为全因死亡、心肌梗死、卒中、冠状动脉血运重建或心力衰竭住院的复合终点。
- 在精神障碍患者中,启动精神药物治疗与主要终点降低44%(校正HR 0.56,95%CI 0.53–0.59)及全因死亡降低49%(校正HR 0.51,95%CI 0.48–0.55)相关。
证据类型、等级与局限
- 证据类型:全国性人群-based队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,心源性休克幸存者中新发精神障碍常见且具有预后意义,应及时进行精神药物干预,并应整合到ICU后照护路径中。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: This study aimed to evaluate the incidence of new-onset mental disorders after cardiogenic shock (CS) and their association with long-term clinical outcomes, and to examine whether the use of psychiatric medications following diagnosis is associated with improved prognosis. METHODS: A nationwide population-based cohort study was performed using the Korean National Health Insurance Service database. All adult patients who were admitted to intensive care units (ICUs) for CS between January 2012 and December 2022 and survived hospital discharge were recruited. Patients with pre-existing psychiatric diagnoses were excluded, Finally, 112,297 patients were included in the current cohort. The primary analysis assessed the association between new-onset psychiatric disorders after hospital discharge and long-term clinical outcomes among survivors of CS, with the onset of newly developed mental disorders treated as a time-varying variable. Among patients diagnosed with a psychiatric disorder, a secondary analysis assessed the association between psychiatric medication use including antidepressants, antipsychotics, anxiolytics, or sedative-hypnotics and clinical outcomes. Medication use was also modeled as a time-varying covariate. The primary endpoint was a composite of all-cause death, myocardial infarction, stroke, coronary revascularization, or heart failure hospitalization. RESULTS: During the median follow-up of 3.5 years (interquartile range: 1.26–6.56), 11,166 CS survivors (9.9%) developed new-onset mental disorders (including depressive disorder, insomnia, anxiety disorder, and schizophrenia spectrum disorder). These disorders were associated with a significantly increased risk of primary endpoint (adjusted-HR:1.08, 95%CI:1.04–1.13), except anxiety disorders. Among patients with mental disorders, initiation of medication for mental disorders was associated with a 44% reduction in the primary endpoint (adjusted-HR:0.56, 95%CI:0.53–0.59) and a 49% reduction in all-cause death (adjusted-HR:0.51, 95%CI:0.48–0.55). CONCLUSIONS: New-onset mental disorders are common and prognostically significant in survivors of CS. Timely pharmacologic intervention for mental disorders may substantially improve long-term clinical outcomes and should be integrated into post-ICU care pathways.
参考来源
- Choi KH, Seo J, Cha JH, et al. Mental health sequelae and management in survivors of cardiogenic shock: a nationwide population-based study. Crit Care. 2026. PMID: 41559811. doi:10.1186/s13054-026-05841-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。